- Home
- MHF vs IMUX Comparison
MHF vs IMUX Comparison
Compare MHF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHF | IMUX |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 155.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | MHF | IMUX |
|---|---|---|
| Price | $6.39 | $10.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 60.8K | ★ 289.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.35 | $0.51 |
| 52 Week High | $7.55 | $17.43 |
Technical Indicators
Market Signals| Indicator | MHF | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 22.41 | 32.37 |
| Support Level | N/A | $0.78 |
| Resistance Level | $7.04 | $15.82 |
| Average True Range (ATR) | 0.09 | 0.94 |
| MACD | -0.03 | -0.28 |
| Stochastic Oscillator | 16.75 | 11.86 |
Price Performance
Historical ComparisonAbout MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.